Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of REGN3500 alone or with dupilumab in adults with moderate-to-severe atopic dermatitis
NL-OMON48003Phase 2Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of itepekimab and dupilumab in atopic dermatitis (AD) (4 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent change in EASI score from baseline to week 16. Started Nov 2018; status: active, not recruiting.
02
Drugs
itepekimabdupilumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON48003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48003.